Aerocrine: Positive reimbursement coverage continues for Aerocrine’s asthma test – The Herald | HeraldOnline.com

Aerocrine: Positive reimbursement coverage continues for Aerocrine's asthma test
The Herald | HeraldOnline.com
Specifically, FeNO testing is covered for the treatment of asthma when it is used in the diagnosis of allergic airway inflammation or when used in determining likelihood of steroid responsiveness in individuals with chronic symptoms suggestive of

View full post on asthma – Google News

Aerocrine’s novel asthma test in search of doctors, insurers [The News … – Insurance News Net (press release)

Aerocrine's novel asthma test in search of doctors, insurers [The News
Insurance News Net (press release)
With $22 million in cash, Aerocrine is positioned to finance operations through 2012, according to one analyst report, putting a premium on increased sales for its relatively unknown asthma test. The 15-year-old company, based on a scientific discovery

View full post on asthma – Google News

Aerocrine: South Carolina Adopts Positive Coverage of Aerocrine’s FeNo Testing … – Business Wire (press release)

Aerocrine: South Carolina Adopts Positive Coverage of Aerocrine's FeNo Testing
Business Wire (press release)
“FeNO testing is a significant advancement in managing the patient with asthma. Since the publication of the American Thoracic Guideline on FeNO, this test should be standard of care in every clinic managing asthma patients.
South Carolina adopts positive coverage of Aerocrine's FeNO testing in CisionWire (press release)

all 2 news articles »

View full post on asthma – Google News

South Carolina adopts positive coverage of Aerocrine’s FeNO testing in … – CisionWire (press release)

South Carolina adopts positive coverage of Aerocrine's FeNO testing in
CisionWire (press release)
Physicians use FeNO to assess eosinophilic airway inflammation, the primary underlying abnormality that affects the airways of individuals who have asthma. NIOX MINO is the only product of its kind currently on the market for assessing FeNO.

and more »

View full post on asthma – Google News

Mississippi’s Medicaid program adds coverage for Aerocrine’s FeNO testing in … – EON: Enhanced Online News (press release)

Mississippi's Medicaid program adds coverage for Aerocrine's FeNO testing in
EON: Enhanced Online News (press release)
Asthma is a chronic inflammatory disease of the airways that affects more than 300 million people worldwide, many of whom are children. FeNO is a marker of the underlying airway inflammation associated with asthma, and Aerocrine has developed a method

and more »

View full post on asthma – Google News

Mississippi’s Medicaid program adds coverage for Aerocrine’s FeNO testing in … – MarketWatch (press release)

Mississippi's Medicaid program adds coverage for Aerocrine's FeNO testing in
MarketWatch (press release)
Asthma is a chronic inflammatory disease of the airways that affects more than 300 million people worldwide, many of whom are children. FeNO is a marker of the underlying airway inflammation associated with asthma, and Aerocrine has developed a method

and more »

View full post on asthma – Google News

Major US Allergy and Asthma Group Practice Adopts Aerocrine’s Technology

Allergy and Asthma Group Practice Adopts Aerocrine’s FENO Testing, Providing Personalized Asthma Management Technology

SOLNA, Sweden – 12 August 2011 – Aerocrine AB today announced that Allergy & Asthma Specialists, P.C. has adopted Aerocrine’s FENO technology for airway inflammation measurement as part of its clinical standardization on a system-wide basis. Allergy & Asthma Specialists, P.C. is the largest group practice in the Philadelphia region specializing in allergic disease, asthma and immunology. Allergists use FENO to diagnose eosinophilic airway inflammation in patients with non-specific respiratory symptoms, to predict patient response to corticosteroid therapy, as well as to optimize dosing and assess adherence to anti-inflammatory therapy.

Allergy & Asthma Specialists, P.C. has eight locations in Philadelphia and surrounding suburbs. “We pride ourselves at providing our patients with the most up to date and comprehensive care,” said Dr. Robert Anolik, President of Allergy & Asthma Specialists, P.C. “Measurement of exhaled nitric oxide will enable us to provide optimal asthma management to our patients.”

“We are delighted to have this prestigious group of Allergy and Asthma Specialists on board with FENO testing, providing personalized asthma management”, said Kathy Hodgdon, Director of Sales & Marketing with Aerocrine. “In less than two minutes, this simple and inexpensive test makes it possible for physicians to better help patients living with asthma with appropriate therapy and disease control based on the patients’ individual needs.”

Asthma is a chronic inflammatory disease of the airways characterized by symptoms including wheezing and difficulty in breathing. The disease affects more than 300 million people around the world, of whom a significant number are children. Aerocrine’s founders made the original discovery that the levels of nitric oxide in exhaled breath, FENO, is elevated in patients with asthma. This has enabled a quick, effective and proactive method to measure the underlying inflammation in asthma, rather than being limited to reactively monitor its negative consequences in the form of symptoms and reduced lung function. The method has significant value in connection with diagnosis and choice of appropriate medication, as well as for the continuous management of asthma which is aimed at controlling the airway inflammation. Today, more than four million patient tests have been performed around the world using Aerocrine’s NIOX products.

For more information, contact:

Kathy Hodgdon, Director of Sales & Marketing, Aerocrine, Inc., telephone (314) 566-8546

Chip Neff, President, Aerocrine, Inc., telephone (919) 696-4267
Paul de Potocki, CEO, telephone: +46 8 629 07 80

For more information about Allergy & Asthma Specialists, please visit www.allergyandasthmawellness.com

About Aerocrine Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in the technology to monitor and manage airway inflammation, Aerocrine markets NIOX® Flex and NIOX MINO®. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June 2007. Aerocrine discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08:00 a.m. on August the 12th 2011.